Vetmedin 1.25mg Chewable Tablets for Dogs

Country: New Zealand

Language: English

Source: Ministry for Primary Industries

Active ingredient:

pimobendan

Available from:

Boehringer Ingelheim Animal Health New Zealand Limited

INN (International Name):

pimobendan

Composition:

pimobendan 2.5 g/kg

Therapeutic area:

Cardiovascular agent

Authorization status:

ACVM Registered

Authorization date:

2007-01-16

Summary of Product characteristics

Product: Vetmedin 1.25 mg Chewable Tablets for Dogs
Date: 9 March 2018
ACVM No.: A009699
Page 1 of 6
BOTTLE LABEL
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Vetmedin
®
1.25 mg
Chewable Tablets for Dogs
Active Constituent:
Each tablet contains 1.25 mg Pimobendan
50 tablets
READ THE ENCLOSED LEAFLET FOR FULL INSTRUCTIONS.
FIRST AID
If poisoning occurs, contact a doctor or Poisons Information Centre.
Phone Australia 131126. New Zealand 0800 764 766 (0800 POISON)
STORAGE
Store below 25 °C (Air Conditioning). Keep the container tightly
closed.
AUSTRALIA
Boehringer Ingelheim Animal Health Australia Pty Limited
Phone: [phone]
APVMA 60800/XXXX/XXXX
NEW ZEALAND INFORMATION
RVM
ACVM No. A009699
See www.foodsafety.govt.nz for registration conditions.
Boehringer Ingelheim Animal Health New Zealand Ltd
Freephone: 0800 800 822
Batch No.:
Expiry Date:
Product: Vetmedin 1.25 mg Chewable Tablets for Dogs
Date: 9 March 2018
ACVM No.: A009699
Page 2 of 6
CARTON LABEL
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Vetmedin
®
1.25 mg
Chewable Tablets for Dogs
Active Constituent:
Each tablet contains 1.25 mg Pimobendan
50 tablets
INDICATIONS
Vetmedin
®
Chewable Tablets are indicated for:
The treatment of canine congestive heart failure (CHF) originating
from dilated
cardiomyopathy (DCM) or valvular insufficiency (mitral and/or
tricuspid regurgitation).
The treatment of preclinical DCM in large breed dogs. When used in
cases of preclinical DCM
in large breed dogs, pimobendan significantly prolonged the time to
the onset of CHF or
sudden death, and also resulted in prolongation of the time to death
due to all causes.
Doberman Pinscher dogs with preclinical DCM treated with pimobendan
also demonstrated a
significant reduction in Left Ventricular Internal Diameter in both
systole and diastole
(LVIDs/d) in response to therapy.
For the treatment of dogs with evidence of increased heart size
secondary to asymptomatic
(preclinical) myxomatous mitral valve dis